Accord Healthcare Recalls Glimepiride Tablets Due to CGMP Deviations
Accord Healthcare is recalling Glimepiride 4 mg tablets due to Current Good Manufacturing Practice deviations discovered during an FDA inspection. Approximately 1.16 million bottles across the United States, Puerto Rico, and Canada are affected.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II precautionary recall with no reported illnesses or injuries. The CGMP deviations represent a manufacturing process violation, but no specific product defect has been confirmed.
Plain-English summary
Accord Healthcare, Inc. is recalling Glimepiride Tablets USP, 4 mg, due to Current Good Manufacturing Practice (CGMP) deviations identified during an FDA inspection. The affected product was manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India and distributed in the United States, Puerto Rico, and Canada.
The recall includes approximately 1,158,839 bottles packaged in 100-count and 500-count containers. Affected batch numbers span multiple production runs with expiration dates ranging from March 31, 2023 through August 31, 2025.
Patients taking the recalled product should not stop their medication without consulting their healthcare provider. Individuals who have this product should contact their pharmacy or healthcare provider for replacement product or guidance.
The recalled product
- Product
- GLIMEPIRIDE (GLIMEPIRIDE)
- Brand
- GLIMEPIRIDE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Prescription Antidiabetic
- Hazard
- Affected units
- 1,158,839
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a) P2001868
- Exp. Date 3/31/2023
- P2001869 Exp. Date 3/31/2023
- P2002810 Exp. Date 5/31/2023
- P2005473 Exp. Date 8/31/2023
- P2005552 Exp. Date 9/30/2023
- P2101986 Exp. Date 3/31/2024
- P2101989 Exp. Date 3/31/2024
- P2101988 Exp. Date 3/31/2024
- P2101991 Exp. Date 3/31/2024
- P2101992 Exp. Date 3/31/2024
- R2100736 Exp. Date 6/30/2024
- R2100737 Exp. Date 6/30/2024
- P2105281 Exp. Date 7/31/2024
- R2101441 Exp. Date 9/30/2024
- R2101454 Exp. Date 10/31/2024
- R2101455 Exp. Date 10/31/2024
- R2101468 Exp. Date 10/31/2024
- R2101469 Exp. Date 10/31/2024
- R2200096 Exp. Date 12/31/2024
UPCs (4)
- 0316729003018
- 0316729002011
- 316729003018
- 316729003162
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same brand · GLIMEPIRIDE
- ModerateFDA Recalls Glimepiride Tablets for Misprint on Tablet
FDA (Drugs) · 2024-02-14
- ModeratePrescription Glimepiride Tablets Recalled Due to Tablet Misprint
FDA (Drugs) · 2024-02-14
- ModerateFDA Recalls Glimepiride Tablets for Manufacturing Deviations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Drug Glimepiride Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2023-05-03
- HighAccord Healthcare recalls Glimepiride tablets due to manufacturing practice deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Accord Healthcare, Inc.
See all →- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · manufacturing deviation
See all →- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateiVIZIA Dry Eye Lubricant Drops Recalled for Sterility Assurance
FDA (Drugs) · 2026-05-06
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29